{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T22:17:01Z","timestamp":1773872221291,"version":"3.50.1"},"reference-count":68,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2024M761135"],"award-info":[{"award-number":["2024M761135"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013061","name":"Jilin Provincial Scientific and Technological Development Program","doi-asserted-by":"publisher","award":["20240303072NC"],"award-info":[{"award-number":["20240303072NC"]}],"id":[{"id":"10.13039\/501100013061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012152","name":"National Postdoctoral Program for Innovative Talents","doi-asserted-by":"publisher","award":["BX20240137"],"award-info":[{"award-number":["BX20240137"]}],"id":[{"id":"10.13039\/501100012152","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.bbadis.2025.167913","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T02:14:59Z","timestamp":1747620899000},"page":"167913","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["mTOR blockade mitigates chemotherapy drug-induced intestinal toxicity via inhibition of pyroptosis"],"prefix":"10.1016","volume":"1871","author":[{"given":"Xinyue","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiyu","family":"Guan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lening","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yicheng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenqi","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbadis.2025.167913_bb0005","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1093\/annonc\/mdw271","article-title":"Chemotherapy remains an essential element of personalized care for persons with lung cancers","volume":"27","author":"Hellmann","year":"2016","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.bbadis.2025.167913_bb0010","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.canlet.2020.09.014","article-title":"Cooperation between chemotherapy and immunotherapy in gastroesophageal cancers","volume":"495","author":"Davern","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbadis.2025.167913_bb0015","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0163-7258(83)90077-3","article-title":"Regional chemotherapy of neoplastic diseases","volume":"21","author":"Ensminger","year":"1983","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bbadis.2025.167913_bb0020","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0305-7372(93)90025-M","article-title":"Chemotherapy of carcinoma of the stomach","volume":"19","author":"Findlay","year":"1993","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bbadis.2025.167913_bb0025","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jconrel.2019.04.020","article-title":"Immunological consequences of chemotherapy: single drugs, combination therapies and nanoparticle-based treatments","volume":"305","author":"Pusuluri","year":"2019","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"10.1016\/j.bbadis.2025.167913_bb0030","first-page":"95","article-title":"Molecular mechanisms of etoposide","volume":"14","author":"Montecucco","year":"2015","journal-title":"EXCLI J."},{"key":"10.1016\/j.bbadis.2025.167913_bb0035","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2165\/00003088-200443070-00002","article-title":"Pharmacokinetic optimisation of treatment with oral etoposide","volume":"43","author":"Toffoli","year":"2004","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.bbadis.2025.167913_bb0040","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nrc2607","article-title":"Targeting DNA topoisomerase II in cancer chemotherapy","volume":"9","author":"Nitiss","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbadis.2025.167913_bb0045","doi-asserted-by":"crossref","first-page":"148","DOI":"10.2478\/raon-2019-0018","article-title":"Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy","volume":"53","author":"Makovec","year":"2019","journal-title":"Radiol. Oncol."},{"key":"10.1016\/j.bbadis.2025.167913_bb0050","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","article-title":"Cisplatin in cancer therapy: molecular mechanisms of action","volume":"740","author":"Dasari","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bbadis.2025.167913_bb0055","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.7150\/thno.69424","article-title":"Platinum-based drugs for cancer therapy and anti-tumor strategies","volume":"12","author":"Zhang","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.bbadis.2025.167913_bb0060","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.biopha.2018.12.010","article-title":"Phytochemicals: current strategy to sensitize cancer cells to cisplatin","volume":"110","author":"Sun","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bbadis.2025.167913_bb0065","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1038\/s41401-023-01093-8","article-title":"Chemotherapy-induced metastasis: molecular mechanisms and clinical therapies","volume":"44","author":"Su","year":"2023","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.bbadis.2025.167913_bb0070","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/sj.bjc.6603048","article-title":"Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy","volume":"94","author":"Vardy","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbadis.2025.167913_bb0075","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1200\/JCO.2000.18.19.3409","article-title":"Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence","volume":"18","author":"Ioannidis","year":"2000","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.bbadis.2025.167913_bb0080","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"issue":"14","key":"10.1016\/j.bbadis.2025.167913_bb0085","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.cub.2004.06.054","article-title":"Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton","volume":"14","author":"Sarbassov","year":"2004","journal-title":"Curr. Biol."},{"key":"10.1016\/j.bbadis.2025.167913_bb0090","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1152\/physrev.00026.2020","article-title":"Regulation and metabolic functions of mTORC1 and mTORC2","volume":"101","author":"Szwed","year":"2021","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.bbadis.2025.167913_bb0095","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nature10912","article-title":"The translational landscape of mTOR signalling steers cancer initiation and metastasis","volume":"485","author":"Hsieh","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.bbadis.2025.167913_bb0100","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.semcancer.2019.05.012","article-title":"Role of the PI3K\/AKT\/mTOR signaling pathway in ovarian cancer: biological and therapeutic significance","volume":"59","author":"Ediriweera","year":"2019","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bbadis.2025.167913_bb0105","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13045-019-0754-1","article-title":"Targeting mTOR for cancer therapy. J. Hematol. Oncol","volume":"12","author":"Hua","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bbadis.2025.167913_bb0110","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer","volume":"22","author":"Glaviano","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbadis.2025.167913_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.semcancer.2019.12.008","article-title":"Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: a novel therapeutic strategy","volume":"80","author":"Tewari","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bbadis.2025.167913_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.semcancer.2019.12.008","article-title":"Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: a novel therapeutic strategy","volume":"80","author":"Tewari","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bbadis.2025.167913_bb0125","doi-asserted-by":"crossref","first-page":"40002","DOI":"10.1074\/jbc.M111.297432","article-title":"Inhibition of mTOR kinase by AZD8055 can antagonize chemotherapy-induced cell death through autophagy induction and down-regulation of p62\/sequestosome 1","volume":"286","author":"Huang","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbadis.2025.167913_bb0130","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.jgr.2021.03.001","article-title":"Panax ginseng and its ginsenosides: potential candidates for the prevention and treatment of chemotherapy-induced side effects","volume":"45","author":"Wan","year":"2021","journal-title":"J. Ginseng Res."},{"key":"10.1016\/j.bbadis.2025.167913_bb0135","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41392-021-00507-5","article-title":"Pyroptosis: mechanisms and diseases","volume":"6","author":"Yu","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bbadis.2025.167913_bb0140","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/s41423-022-00905-x","article-title":"Role of pyroptosis in inflammation and cancer","volume":"19","author":"Wei","year":"2022","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.bbadis.2025.167913_bb0145","doi-asserted-by":"crossref","first-page":"4310","DOI":"10.7150\/thno.71086","article-title":"Pyroptosis in inflammatory diseases and cancer","volume":"12","author":"Rao","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.bbadis.2025.167913_bb0150","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.tibs.2016.10.004","article-title":"Pyroptosis: Gasdermin-mediated programmed necrotic cell death","volume":"42","author":"Shi","year":"2017","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.bbadis.2025.167913_bb0155","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nature22393","article-title":"Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin","volume":"547","author":"Wang","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.bbadis.2025.167913_bb0160","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41419-021-03458-5","article-title":"Caspase 3\/GSDME-dependent pyroptosis contributes to chemotherapy drug-induced nephrotoxicity","volume":"12","author":"Shen","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbadis.2025.167913_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2024.101865","article-title":"To die or not to die: Gasdermins in intestinal health and disease","volume":"71","author":"Lin","year":"2024","journal-title":"Semin. Immunol."},{"issue":"24","key":"10.1016\/j.bbadis.2025.167913_bb0170","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1016\/j.scib.2024.05.021","article-title":"Western diet induces Gsdme-mediated epithelial pyroptosis through the DCA-S1PR2 pathway to disrupt the intestinal epithelial barrier","volume":"69","author":"Liu","year":"2024","journal-title":"Sci. Bull."},{"key":"10.1016\/j.bbadis.2025.167913_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2013.06.017","article-title":"mTOR kinase inhibitors as potential cancer therapeutic drugs","volume":"340","author":"Sun","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbadis.2025.167913_bb0180","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.7150\/thno.81406","article-title":"The STAT1\/HMGB1\/NF-\u03baB pathway in chronic inflammation and kidney injury after cisplatin exposure","volume":"13","author":"Fu","year":"2023","journal-title":"Theranostics"},{"key":"10.1016\/j.bbadis.2025.167913_bb0185","doi-asserted-by":"crossref","first-page":"784","DOI":"10.7150\/ijbs.82003","article-title":"Inhibition of the HMGB1\/RAGE axis protects against cisplatin-induced ototoxicity via suppression of inflammation and oxidative stress","volume":"20","author":"Qiao","year":"2024","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.bbadis.2025.167913_bb0190","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1152\/physrev.00026.2013","article-title":"Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release","volume":"94","author":"Zorov","year":"2014","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.bbadis.2025.167913_bb0195","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ymeth.2016.06.008","article-title":"Quantifying ROS levels using CM-H2DCFDA and HyPer","volume":"109","author":"Oparka","year":"2016","journal-title":"Methods San Diego Calif"},{"key":"10.1016\/j.bbadis.2025.167913_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2018.101084","article-title":"ROS and the DNA damage response in cancer","volume":"25","author":"Srinivas","year":"2019","journal-title":"Redox Biol."},{"key":"10.1016\/j.bbadis.2025.167913_bb0205","doi-asserted-by":"crossref","first-page":"7603","DOI":"10.7150\/thno.75966","article-title":"Intravital molecular imaging reveals that ROS-caspase-3-GSDME-induced cell punching enhances humoral immunotherapy targeting intracellular tumor antigens","volume":"12","author":"Dai","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.bbadis.2025.167913_bb0210","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/bjc.2012.368","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma","volume":"107","author":"Naing","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbadis.2025.167913_bb0215","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.cmet.2015.06.006","article-title":"Redox homeostasis and mitochondrial dynamics","volume":"22","author":"Willems","year":"2015","journal-title":"Cell Metab."},{"key":"10.1016\/j.bbadis.2025.167913_bb0220","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.bbadis.2016.11.010","article-title":"Mitochondrial dysfunction and oxidative stress in metabolic disorders - a step towards mitochondria based therapeutic strategies","volume":"1863","author":"Bhatti","year":"2017","journal-title":"Biochim. Biophys. Acta Mol. basis Dis."},{"key":"10.1016\/j.bbadis.2025.167913_bb0225","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1146\/annurev.arplant.55.031903.141701","article-title":"Reactive oxygen species: metabolism, oxidative stress, and signal transduction","volume":"55","author":"Apel","year":"2004","journal-title":"Annu. Rev. Plant Biol."},{"key":"10.1016\/j.bbadis.2025.167913_bb0230","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/sj.cdd.4400476","article-title":"Emerging roles of caspase-3 in apoptosis","volume":"6","author":"Porter","year":"1999","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.bbadis.2025.167913_bb0235","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/s41419-023-06382-y","article-title":"The multifaceted roles of GSDME-mediated pyroptosis in cancer: therapeutic strategies and persisting obstacles","volume":"14","author":"Hu","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbadis.2025.167913_bb0240","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1158\/2326-6066.CIR-20-0525","article-title":"Lighting a fire: can we harness Pyroptosis to ignite antitumor immunity?","volume":"9","author":"Zhang","year":"2021","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.bbadis.2025.167913_bb0245","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41586-020-2071-9","article-title":"Gasdermin E suppresses tumour growth by activating anti-tumour immunity","volume":"579","author":"Zhang","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bbadis.2025.167913_bb0250","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41467-017-00213-3","article-title":"Hypoxia ameliorates intestinal inflammation through NLRP3\/mTOR downregulation and autophagy activation","volume":"8","author":"Cosin-Roger","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbadis.2025.167913_bb0255","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1080\/15548627.2019.1635384","article-title":"New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD","volume":"16","author":"Larabi","year":"2020","journal-title":"Autophagy"},{"key":"10.1016\/j.bbadis.2025.167913_bb0260","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1080\/15548627.2023.2259214","article-title":"Autophagy in colitis-associated colon cancer: exploring its potential role in reducing initiation and preventing IBD-related CAC development","volume":"20","author":"Jin","year":"2024","journal-title":"Autophagy"},{"key":"10.1016\/j.bbadis.2025.167913_bb0265","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1111\/jgh.16381","article-title":"Rapamycin extenuates experimental colitis by modulating the gut microbiota","volume":"38","author":"Guo","year":"2023","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"8","key":"10.1016\/j.bbadis.2025.167913_bb0270","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.2174\/0929867327666200504081503","article-title":"Targeting mammalian target of rapamycin: prospects for the treatment of inflammatory bowel diseases","volume":"28","author":"Lashgari","year":"2021","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bbadis.2025.167913_bb0275","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1038\/leu.2008.204","article-title":"Rapamycin reverses NPM-ALK-induced glucocorticoid resistance in lymphoid tumor cells by inhibiting mTOR signaling pathway, enhancing G1 cell cycle arrest and apoptosis","volume":"22","author":"Gu","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.bbadis.2025.167913_bb0280","doi-asserted-by":"crossref","first-page":"1297408","DOI":"10.3389\/fimmu.2023.1297408","article-title":"Advances in the regulatory mechanisms of mTOR in necroptosis","volume":"14","author":"Xie","year":"2023","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.bbadis.2025.167913_bb0285","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1158\/1078-0432.CCR-12-0061","article-title":"Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors","volume":"18","author":"Naing","year":"2012","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.bbadis.2025.167913_bb0290","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S1470-2045(14)71136-2","article-title":"Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial","volume":"16","author":"Grignani","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbadis.2025.167913_bb0295","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","article-title":"Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"381","author":"Bissler","year":"2013","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.bbadis.2025.167913_bb0300","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1056\/NEJMoa1100391","article-title":"Efficacy and safety of sirolimus in lymphangioleiomyomatosis","volume":"364","author":"McCormack","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2025.167913_bb0305","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa063564","article-title":"Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis","volume":"358","author":"Bissler","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2025.167913_bb0310","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1200\/JCO.2010.33.4649","article-title":"Phase I study of temsirolimus in pediatric patients with recurrent\/refractory solid tumors","volume":"29","author":"Spunt","year":"2011","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.bbadis.2025.167913_bb0315","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1200\/JCO.2007.11.4017","article-title":"Phase I study of everolimus in pediatric patients with refractory solid tumors","volume":"25","author":"Fouladi","year":"2007","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.bbadis.2025.167913_bb0320","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/S1470-2045(24)00202-X","article-title":"Irinotecan and temozolomide in combination with dasatinib and rapamycin versus irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma (RIST-rNB-2011): a multicentre, open-label, randomised, controlled, phase 2 trial","volume":"25","author":"Corbacioglu","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbadis.2025.167913_bb0325","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S1470-2045(17)30355-8","article-title":"Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial","volume":"18","author":"Mody","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbadis.2025.167913_bb0330","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa042831","article-title":"Sirolimus for Kaposi\u2019s sarcoma in renal-transplant recipients","volume":"352","author":"Stallone","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2025.167913_bb0335","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.phrs.2004.03.007","article-title":"mTOR: a protein kinase switching between life and death","volume":"50","author":"Asnaghi","year":"2004","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bbadis.2025.167913_bb0340","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.canlet.2010.04.015","article-title":"mTOR inhibition by everolimus counteracts VEGF induction by sunitinib and improves anti-tumor activity against gastric cancer in vivo","volume":"296","author":"Fuereder","year":"2010","journal-title":"Cancer Lett."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443925002613?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443925002613?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T06:28:50Z","timestamp":1762324130000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0925443925002613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":68,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0925443925002613"],"URL":"https:\/\/doi.org\/10.1016\/j.bbadis.2025.167913","relation":{},"ISSN":["0925-4439"],"issn-type":[{"value":"0925-4439","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"mTOR blockade mitigates chemotherapy drug-induced intestinal toxicity via inhibition of pyroptosis","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbadis.2025.167913","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"167913"}}